Frank ZhangHead of Market Access at uniQure
Frank Zhang is currently Head of Market Access for uniQure preparing for commercialization of first gene therapy in Hemophilia B and Huntingdon’s Disease. Prior to this position, he was with Alnylam from 2017-2019 as VP, Global and US Market Access, and launched the first RNAi product called Onpattro. He was with Celgene from 2010-2017 as Head of Market Access for Immunology and Inflammation Franchise, and launched Otezla successfully in over 25 countries. He was leading HEOR, pricing and market access for Virology franchise for J&J from 2005-2010, and was with Eli Lilly and GSK in his earlier career. Frank was a physician by training and had a Master of Public Health from Yale.